Lab
Mayo Collaborative Services, INC
Mayo Collaborative Services, INC was paid $39.20M by Medicaid between Jan 2018 and Dec 2024, across 344 billing codes. Its largest line is U0003, Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r — 43% of everything it billed.
33Billing provider infoMAYO COLLABORATIVE SERVICES, INC
ROCHESTER, MN 55905
ROCHESTER, MN 55905
33aNPI1093792350assigned 12/28/2005
33bProvider typeClinical Medical Laboratory
28Total paid$39.20M
24GClaims1,085,431
24DCodes billed344
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Clinical Medical Laboratory providers in Minnesota
Rank by total paid#4 of 69
Median peer was paid$48K
This provider vs. median812×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 77,299 | $1.67M | |
| 2019 | 70,485 | $1.83M | |
| 2020 | 170,827 | $9.72M | |
| 2021 | 341,323 | $11.80M | |
| 2022 | 196,882 | $6.56M | |
| 2023 | 123,634 | $3.89M | |
| 2024incomplete | 104,981 | $3.72M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 43% | 276,894 | 161,040 | $16.97M |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 7.0% | 162,290 | 87,761 | $2.74M |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | 3.7% | 9,943 | 7,448 | $1.46M |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 3.6% | 19,627 | 16,049 | $1.40M |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 2.8% | 23,664 | 18,313 | $1.09M |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | 2.0% | 9,356 | 8,441 | $800K |
| 87631 | 1.9% | 6,432 | 6,253 | $735K | |
| 87902 | 1.8% | 3,430 | 3,118 | $724K | |
| 83655 | 1.8% | 45,840 | 44,666 | $688K | |
| 87522 | Neg quan hep c or qual rna | 1.2% | 12,945 | 12,012 | $480K |
| 86003 | 1.2% | 11,717 | 9,840 | $474K | |
| 86480 | 1.2% | 9,344 | 8,994 | $461K |
332 more codes
| 84403 | <1% | 16,219 | $350K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 14,795 | $332K |
| 81511 | <1% | 2,694 | $307K | |
| 83516 | <1% | 15,888 | $272K | |
| 88341 | <1% | 2,452 | $263K | |
| 88185 | <1% | 1,929 | $245K | |
| 84402 | <1% | 12,103 | $243K | |
| 83520 | <1% | 12,063 | $198K | |
| 86235 | <1% | 3,112 | $196K | |
| 87536 | <1% | 2,808 | $195K | |
| 81229 | <1% | 577 | $185K | |
| 88350 | <1% | 927 | $179K | |
| 86364 | <1% | 6,633 | $172K | |
| 81376 | <1% | 1,205 | $171K | |
| 86255 | <1% | 6,548 | $170K | |
| 86481 | <1% | 2,058 | $165K | |
| 87529 | <1% | 2,727 | $151K | |
| 88342 | <1% | 3,474 | $139K | |
| G0476 | Infectious agent detection by nucleic acid (dna or rna); human papillomavirus (hpv), high-risk types (e.g., 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68) for cervical cancer screening, must be performed in addition to pap test | <1% | 4,412 | $136K |
| 86038 | <1% | 12,657 | $132K | |
| 81220 | CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants | <1% | 532 | $129K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 1,889 | $125K |
| 82784 | <1% | 11,173 | $119K | |
| 82105 | <1% | 8,048 | $117K | |
| 86360 | <1% | 3,042 | $116K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 3,122 | $108K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 3,110 | $107K |
| 86803 | <1% | 8,866 | $107K | |
| 83013 | <1% | 1,705 | $99K | |
| 87507 | <1% | 252 | $99K | |
| 82024 | <1% | 2,961 | $98K | |
| 86200 | <1% | 8,835 | $96K | |
| 86359 | <1% | 3,073 | $95K | |
| 88323 | <1% | 2,020 | $95K | |
| 86696 | <1% | 5,559 | $92K | |
| 84425 | <1% | 5,477 | $91K | |
| 84445 | <1% | 2,214 | $88K | |
| 81206 | <1% | 1,059 | $87K | |
| 88184 | <1% | 2,023 | $84K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,415 | $82K |
| 81528 | Oncology (colorectal) screening, quantitative real-time target and signal amplification | <1% | 365 | $82K |
| 83498 | <1% | 3,677 | $81K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 593 | $80K |
| 87497 | <1% | 3,598 | $80K | |
| 87799 | <1% | 2,726 | $77K | |
| 87517 | <1% | 2,058 | $75K | |
| 84305 | <1% | 4,161 | $75K | |
| 88325 | <1% | 1,005 | $75K | |
| 83921 | <1% | 4,279 | $72K | |
| 82627 | <1% | 3,563 | $71K | |
| 83993 | <1% | 4,040 | $70K | |
| 81596 | <1% | 1,412 | $67K | |
| 86147 | <1% | 1,710 | $66K | |
| 84207 | <1% | 2,847 | $66K | |
| 86695 | <1% | 5,556 | $63K | |
| 88321 | <1% | 1,357 | $62K | |
| 84410 | <1% | 1,578 | $62K | |
| 86341 | <1% | 2,989 | $61K | |
| 86376 | <1% | 4,896 | $60K | |
| 80175 | <1% | 5,979 | $60K | |
| 82785 | <1% | 3,910 | $57K | |
| 82088 | <1% | 1,687 | $56K | |
| 80177 | <1% | 5,180 | $56K | |
| 86787 | <1% | 5,486 | $55K | |
| 86317 | <1% | 1,506 | $55K | |
| 86665 | <1% | 1,899 | $55K | |
| 86618 | <1% | 3,577 | $55K | |
| 83021 | <1% | 3,945 | $53K | |
| 84630 | <1% | 5,256 | $53K | |
| 86800 | <1% | 4,195 | $53K | |
| 82652 | <1% | 2,002 | $52K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 1,702 | $51K |
| 82239 | <1% | 3,578 | $51K | |
| 85390 | <1% | 3,657 | $51K | |
| 82525 | <1% | 4,154 | $48K | |
| 83519 | <1% | 2,075 | $47K | |
| 85397 | <1% | 1,765 | $45K | |
| 88313 | <1% | 851 | $44K | |
| 80197 | <1% | 4,124 | $44K | |
| 83020 | <1% | 4,244 | $43K | |
| 86762 | <1% | 3,222 | $42K | |
| 86812 | <1% | 1,892 | $42K | |
| 86708 | <1% | 3,906 | $41K | |
| 82542 | <1% | 2,048 | $40K | |
| 86704 | <1% | 3,854 | $38K | |
| 84590 | <1% | 4,131 | $38K | |
| 88271 | <1% | 809 | $38K | |
| 82103 | <1% | 3,561 | $37K | |
| 86225 | <1% | 3,234 | $36K | |
| 88346 | <1% | 867 | $36K | |
| 81270 | <1% | 770 | $35K | |
| 88291 | <1% | 2,501 | $35K | |
| 84244 | <1% | 2,083 | $35K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 1,925 | $35K |
| 82670 | <1% | 1,565 | $34K | |
| 86780 | <1% | 3,043 | $34K | |
| 86666 | <1% | 2,257 | $32K | |
| 88360 | <1% | 371 | $32K | |
| 86146 | <1% | 876 | $32K | |
| 85246 | <1% | 1,638 | $32K | |
| 86769 | <1% | 873 | $32K | |
| 87340 | <1% | 3,367 | $29K | |
| 84432 | <1% | 2,367 | $29K | |
| 84446 | <1% | 2,577 | $29K | |
| 82677 | <1% | 1,175 | $27K | |
| 87563 | <1% | 638 | $27K | |
| 83525 | <1% | 2,576 | $27K | |
| 83835 | <1% | 1,728 | $26K | |
| 86160 | <1% | 1,509 | $25K | |
| 86381 | <1% | 1,206 | $25K | |
| 84702 | <1% | 1,964 | $25K | |
| 88188 | <1% | 679 | $24K | |
| 83521 | <1% | 917 | $24K | |
| 85240 | <1% | 1,658 | $24K | |
| 86664 | <1% | 1,889 | $24K | |
| 82787 | <1% | 1,017 | $23K | |
| 84681 | <1% | 1,509 | $23K | |
| 86617 | <1% | 1,001 | $23K | |
| 88187 | <1% | 855 | $23K | |
| 81222 | <1% | 109 | $23K | |
| 84165 | <1% | 2,717 | $22K | |
| 86300 | <1% | 1,633 | $22K | |
| 88264 | <1% | 443 | $22K | |
| 87338 | <1% | 1,755 | $22K | |
| 82390 | <1% | 2,297 | $21K | |
| 86355 | <1% | 718 | $21K | |
| 82365 | <1% | 1,829 | $20K | |
| 86682 | <1% | 1,913 | $20K | |
| 88377 | <1% | 100 | $20K | |
| 86753 | <1% | 2,113 | $20K | |
| 80074 | <1% | 420 | $20K | |
| 88275 | <1% | 337 | $20K | |
| 88237 | <1% | 447 | $20K | |
| 86336 | <1% | 1,332 | $20K | |
| 83883 | <1% | 1,096 | $19K | |
| 86706 | <1% | 1,990 | $19K | |
| 87209 | <1% | 1,307 | $19K | |
| 80299 | <1% | 1,130 | $19K | |
| 86015 | <1% | 1,390 | $18K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 588 | $18K |
| 84999 | <1% | 244 | $18K | |
| 86036 | <1% | 664 | $18K | |
| 80183 | <1% | 1,578 | $17K | |
| 82671 | <1% | 671 | $17K | |
| 82157 | <1% | 719 | $17K | |
| 83002 | <1% | 999 | $17K | |
| 86694 | <1% | 1,637 | $16K | |
| 82139 | <1% | 837 | $16K | |
| 85613 | <1% | 1,585 | $16K | |
| 80159 | <1% | 1,319 | $16K | |
| 86337 | <1% | 802 | $15K | |
| 86357 | <1% | 484 | $14K | |
| 84080 | <1% | 1,107 | $14K | |
| 84480 | <1% | 1,138 | $14K | |
| 82610 | <1% | 1,059 | $14K | |
| 82668 | <1% | 817 | $13K | |
| 84146 | <1% | 674 | $13K | |
| 86162 | <1% | 803 | $13K | |
| 82104 | <1% | 1,456 | $13K | |
| 83090 | <1% | 1,020 | $13K | |
| 82626 | <1% | 630 | $13K | |
| 83001 | <1% | 782 | $13K | |
| 81241 | <1% | 268 | $12K | |
| 0077U | <1% | 709 | $12K | |
| 82164 | <1% | 1,214 | $12K | |
| 82653 | <1% | 714 | $12K | |
| 86039 | <1% | 1,542 | $11K | |
| 81329 | <1% | 136 | $11K | |
| 80235 | <1% | 768 | $11K | |
| 86735 | <1% | 878 | $10K | |
| 84255 | <1% | 495 | $10K | |
| 88348 | <1% | 44 | $10K | |
| 86765 | <1% | 941 | $10K | |
| 87177 | <1% | 1,303 | $9K | |
| 84238 | <1% | 423 | $9K | |
| 85306 | <1% | 741 | $9K | |
| 84481 | <1% | 794 | $9K | |
| 80364 | <1% | 1,283 | $9K | |
| 88381 | <1% | 128 | $9K | |
| 84270 | <1% | 488 | $9K | |
| 82607 | <1% | 785 | $9K | |
| 82085 | <1% | 1,033 | $8K | |
| 86053 | <1% | 347 | $8K | |
| 80165 | <1% | 736 | $8K | |
| 81256 | <1% | 201 | $8K | |
| 80201 | <1% | 894 | $8K | |
| 86645 | <1% | 568 | $8K | |
| 86363 | <1% | 286 | $8K | |
| 81339 | <1% | 106 | $8K | |
| 81240 | <1% | 203 | $8K | |
| 84155 | <1% | 2,750 | $8K | |
| 85730 | <1% | 1,763 | $7K | |
| 81219 | <1% | 98 | $7K | |
| 84482 | <1% | 598 | $7K | |
| 80349 | <1% | 514 | $7K | |
| 82166 | <1% | 242 | $7K | |
| 82533 | <1% | 544 | $7K | |
| 82530 | <1% | 517 | $7K | |
| 80164 | <1% | 725 | $7K | |
| 87350 | <1% | 692 | $6K | |
| 86644 | <1% | 513 | $6K | |
| 82379 | <1% | 479 | $6K | |
| 84144 | <1% | 382 | $6K | |
| 86709 | <1% | 520 | $5K | |
| 86747 | <1% | 220 | $5K | |
| 85610 | <1% | 1,755 | $5K | |
| 83970 | <1% | 112 | $5K | |
| 87469 | <1% | 154 | $5K | |
| 82570 | <1% | 1,066 | $5K | |
| 87468 | <1% | 146 | $4K | |
| 87484 | <1% | 146 | $4K | |
| 83825 | <1% | 312 | $4K | |
| 81207 | <1% | 57 | $4K | |
| 82175 | <1% | 269 | $4K | |
| 86705 | <1% | 459 | $4K | |
| 83695 | <1% | 413 | $4K | |
| 82300 | <1% | 233 | $4K | |
| 81508 | <1% | 59 | $4K | |
| 86231 | <1% | 371 | $4K | |
| 86707 | <1% | 387 | $4K | |
| 86698 | <1% | 140 | $4K | |
| 86592 | <1% | 1,013 | $4K | |
| 82180 | <1% | 515 | $4K | |
| 80203 | <1% | 374 | $4K | |
| 82140 | <1% | 300 | $3K | |
| 85303 | <1% | 334 | $3K | |
| 87077 | <1% | 244 | $3K | |
| 87478 | <1% | 96 | $3K | |
| 86258 | <1% | 181 | $3K | |
| 86316 | <1% | 156 | $3K | |
| 87449 | <1% | 325 | $3K | |
| 84075 | <1% | 714 | $3K | |
| 0001M | <1% | 277 | $3K | |
| 82657 | <1% | 131 | $2K | |
| 86635 | <1% | 234 | $2K | |
| 85660 | <1% | 525 | $2K | |
| 87046 | <1% | 138 | $2K | |
| 83789 | <1% | 130 | $2K | |
| 81403 | <1% | 12 | $2K | |
| 80347 | <1% | 655 | $2K | |
| 86778 | <1% | 139 | $2K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 133 | $2K |
| 86215 | <1% | 209 | $2K | |
| 82017 | <1% | 140 | $2K | |
| 82172 | <1% | 121 | $2K | |
| 87634 | <1% | 33 | $2K | |
| 86777 | <1% | 140 | $2K | |
| 83919 | <1% | 97 | $2K | |
| 85670 | <1% | 497 | $2K | |
| 86431 | <1% | 366 | $1K | |
| 82397 | <1% | 148 | $1K | |
| 80324 | <1% | 118 | $1K | |
| 80053 | Comprehensive metabolic panel | <1% | 85 | $1K |
| 87186 | <1% | 98 | $1K | |
| 84597 | <1% | 132 | $1K | |
| 86596 | <1% | 104 | $1K | |
| 83945 | <1% | 91 | $1K | |
| 82507 | <1% | 51 | $1K | |
| 86301 | <1% | 55 | $1K | |
| 87581 | <1% | 31 | $1K | |
| 80356 | <1% | 79 | $1K | |
| 86334 | <1% | 62 | $1K | |
| 83550 | <1% | 128 | $1K | |
| 84166 | <1% | 83 | $1K | |
| 80230 | <1% | 36 | $1K | |
| 81243 | <1% | 49 | $1K | |
| 85300 | <1% | 121 | $1K | |
| 82746 | <1% | 74 | $983.26 | |
| 82340 | <1% | 213 | $960.84 | |
| 82330 | <1% | 95 | $945.03 | |
| 86041 | <1% | 46 | $865.84 | |
| 83540 | <1% | 133 | $858.98 | |
| 85247 | <1% | 24 | $848.55 | |
| 80359 | <1% | 118 | $758.91 | |
| 81269 | <1% | 12 | $754.30 | |
| 87045 | <1% | 135 | $748.44 | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 74 | $699.27 |
| 86611 | <1% | 28 | $698.87 | |
| 80180 | <1% | 77 | $695.28 | |
| 86304 | <1% | 43 | $674.25 | |
| 86788 | <1% | 56 | $659.67 | |
| 82955 | <1% | 90 | $643.46 | |
| 86789 | <1% | 56 | $619.98 | |
| 82679 | <1% | 29 | $535.23 | |
| 82985 | <1% | 54 | $496.95 | |
| 0097U | <1% | 41 | $486.24 | |
| 85384 | <1% | 75 | $474.06 | |
| 84163 | <1% | 26 | $463.07 | |
| 86850 | <1% | 60 | $440.23 | |
| 87476 | <1% | 14 | $437.64 | |
| 86008 | <1% | 19 | $432.18 | |
| 86141 | <1% | 33 | $425.37 | |
| 85379 | <1% | 58 | $388.47 | |
| 83935 | <1% | 71 | $373.44 | |
| 82595 | <1% | 74 | $363.93 | |
| 84433 | <1% | 13 | $348.88 | |
| 84436 | <1% | 45 | $338.31 | |
| 83735 | <1% | 62 | $328.25 | |
| 80145 | <1% | 13 | $315.46 | |
| 80186 | <1% | 46 | $307.38 | |
| 84156 | <1% | 81 | $246.43 | |
| 86140 | <1% | 43 | $243.07 | |
| 86738 | <1% | 16 | $240.33 | |
| 84153 | <1% | 12 | $238.58 | |
| 86060 | <1% | 38 | $237.17 | |
| 84439 | <1% | 35 | $227.55 | |
| 82585 | <1% | 17 | $222.60 | |
| 87116 | <1% | 16 | $204.70 | |
| 83497 | <1% | 15 | $176.79 | |
| 81599 | <1% | 26 | $169.00 | |
| 87899 | <1% | 13 | $162.71 | |
| 86612 | <1% | 14 | $155.37 | |
| 84210 | <1% | 12 | $153.53 | |
| 86366 | <1% | 13 | $150.13 | |
| 84300 | <1% | 38 | $142.13 | |
| 86901 | <1% | 50 | $128.39 | |
| 86900 | <1% | 51 | $128.39 | |
| 80346 | <1% | 14 | $103.73 | |
| 80171 | <1% | 13 | $101.27 | |
| 84105 | <1% | 25 | $99.73 | |
| G0475 | Hiv antigen/antibody, combination assay, screening | <1% | 40 | $72.90 |
| 80185 | <1% | 14 | $50.51 | |
| 80326 | <1% | 1,276 | $50.05 | |
| 82436 | <1% | 12 | $46.43 | |
| 84540 | <1% | 13 | $44.91 | |
| 88141 | <1% | 13 | $40.92 | |
| 84560 | <1% | 12 | $35.94 | |
| 82040 | <1% | 15 | $35.78 | |
| 84133 | <1% | 12 | $33.48 | |
| 83986 | <1% | 13 | $29.02 | |
| 80368 | <1% | 14 | $17.88 | |
| 0065U | 0% | 17 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMEADE, BRIAN (CHIEF OPERATING OFFICER)
| Provider | Location | Paid |
|---|---|---|
| Brian Meade DDS MS PC | Ypsilanti, MI | $1K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.